Vascular Biology and Metabolism (VAM)

Overview

The VAM area was created to allow a comprehensive, cooperative and multidisciplinary approach in basic, clinical and epidemiology research. The ultimate goal is the innovation and transfer of solutions in a group of diseases that are closely interrelated and that constitute the leading cause of morbidity and mortality in the world: cardio-cerebrovascular disease, diabetes-metabolic syndrome and renal impairment. The VAM area includes preclinical and clinical research staff from our center, and collaborative work with groups of the highest international prestige. VAM area includes 8 groups: Cardiovascular Pathology, Diabetes and Metabolism, Nephrology, Ophthalmology (focused on retinal vascular disease), CIBBIM-Nanomedicine and Kidney Physiopathology, Medical Molecular Imaging, Neurovascular Diseases, and Research on Aging, Frailty and Transitions in Barcelona. All groups use an integrative tridimensional approach to generate knowledge on the mechanisms of diseases to generate new diagnostic and therapeutic tools.

Publications

248

total

1470

impact factor

5.93

average impact factor

Group Leader: Rafael Simó

team

group-zoom

zoom

group-download

download

-We finished the EUROCONDOR project funded by the EC (FP7-HEATH-278040). This project, coordinated by Prof. Simó, included a clinical trial that demonstrated for the first time that topical administration of neuroprotective drugs prevent the progression of retinal neurodegeneration in type 2 diabetic patients.

-We demonstrated that the assessment of retinal sensitivity in combination with parameters of fixation by using microperimetry could be a reliable method for detecting prodromal stages of dementia in the type 2 diabetic population. This finding is the basis of the RECOGNISED project coordinated by Prof. Simó and funded by the EC in 2019 (GA 847749).

-We have identified several SNPs for predicting the rate of sustained weight loss and diabetes remission after bariatric surgery.

-We have shown that diabetic retinopathy is an independent and powerful risk factor for subclinical cardiovascular disease.

35

total

179

impact factor

5^.12

average impact factor

SELECTED ARTICLES

Simó R, Hernández C, Porta M, Bandello F, Grauslund J, Harding SP, Aldington SJ, Egan C, Frydkjaer-Olsen U, García-Arumí J, Gibson J, Lang GE, Lattanzio R, Massin P, Midena E, Ponsati B, Ribeiro L, Scanlon P, Lobo C, Costa MÂ, Cunha-Vaz J; European Consortium for the Early Treatment of Diabetic Retinopathy (EUROCONDOR).
Effects of Topically Administered Neuroprotective Drugs in Early Stages of Diabetic Retinopathy: Results of the EUROCONDOR Clinical Trial.
Diabetes. 2019 Feb;68(2):457-463.
doi: 10.2337/db18-0682
IF: 7.199
Sampedro J, Bogdanov P, Ramos H, Solà-Adell C, Turch M, Valeri M, Simó-Servat O, Lagunas C, Simó R, Hernández C.
New Insights into the Mechanisms of Action of Topical Administration of GLP-1 in an Experimental Model of Diabetic Retinopathy.
J Clin Med. 2019 Mar 11;8(3). pii: E339.
doi: 10.3390/jcm8030339
IF: 6.78
Simó-Servat O, Ciudin A, Ortiz-Zúñiga ÁM, Hernández C, Simó R.
Usefulness of Eye Fixation Assessment for Identifying Type 2 Diabetic Subjects at Risk of Dementia.
J Clin Med. 2019 Jan 8;8(1). pii: E59.
doi: 10.3390/jcm8010059
IF: 6.78
Ciudin A, Fidilio E, Ortiz A, Pich S, Salas E, Mesa J, Hernández C, Simó-Servat O, Lecube A, Simó R.
Genetic Testing to Predict Weight Loss and Diabetes Remission and Long-Term Sustainability after Bariatric Surgery: A Pilot Study.
J Clin Med. 2019 Jul 3;8(7).
IF: 6.78
Simó R, Bañeras J, Hernández C, Rodríguez-Palomares J, Valente F, Gutierrez L, González-Alujas T, Ferreira I, Aguadé-Bruix S, Montaner J, Seron D, Genescà J, Boixadera A, García-Arumí J, Planas A, Simó-Servat O, García-Dorado D.
Diabetic retinopathy as an independent predictor of subclinical cardiovascular disease: baseline results of the PRECISED study.
BMJ Open Diabetes Res Care. 2019 Dec 29;7(1):e000845.
doi: 10.1136/bmjdrc-2019-000845
IF: 1.534

View all publications